Daiki Ogawara
Fukuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
Journal: Scientific reports
Published: April 03, 2022
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
Journal: Thoracic cancer
Published: November 15, 2018
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Journal: Thoracic cancer
Published: November 01, 2018
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 14, 2018
Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G.
Journal: Thoracic cancer
Published: March 13, 2018
Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.
Journal: Thoracic cancer
Published: September 21, 2017
Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy.
Journal: Thoracic cancer
Published: August 22, 2017
Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M.
Journal: Thoracic cancer
Published: August 06, 2017
Last Updated: 09/26/2026